Tandem Diabetes Care (TNDM) Stock Forecast & Price Target

Compare

1,456 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TNDM Analyst Ratings

Moderate Buy

6 Buy

9 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Tandem

Diabetes Care

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TNDM Stock 12 Month Forecast

Average Price Target

$30.71

▲(40.16% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Tandem Diabetes Care in the last 3 months. The average price target is $30.71 with a high forecast of $56.00 and a low forecast of $22.00. The average price target represents a 40.16% change from the last price of $21.91.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","34":"$34","57":"$57","22.5":"$22.5","45.5":"$45.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,22.5,34,45.5,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.23,27.596923076923076,29.963846153846156,32.33076923076923,34.69769230769231,37.06461538461538,39.43153846153846,41.79846153846154,44.16538461538461,46.53230769230769,48.89923076923077,51.26615384615384,53.63307692307692,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.23,25.65153846153846,26.073076923076922,26.494615384615386,26.916153846153847,27.337692307692308,27.75923076923077,28.180769230769233,28.602307692307694,29.023846153846154,29.445384615384615,29.86692307692308,30.28846153846154,{"y":30.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.23,24.981538461538463,24.733076923076922,24.484615384615385,24.236153846153847,23.987692307692306,23.73923076923077,23.49076923076923,23.242307692307694,22.993846153846153,22.745384615384616,22.49692307692308,22.248461538461537,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.73,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.98,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.78,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 54, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.98,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 56, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.23,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 55, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$56.00

Average Price Target$30.71

Lowest Price Target$22.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew O'Brien

Piper Sandler

$21→$33

Buy

50.62%

Upside

Upgraded

03/17/26

Tandem Diabetes upgraded to Overweight from Neutral at Piper SandlerTandem Diabetes upgraded to Overweight from Neutral at Piper Sandler

Joanne Wuensch

Citi

$22

Hold

0.41%

Upside

Reiterated

03/11/26

Citi Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM)

Travis Steed

Bank of America Securities

$30→$35

Hold

59.74%

Upside

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (NASDAQ: VIR), Tandem Diabetes Care (NASDAQ: TNDM) and Hims & Hers Health (NYSE: HIMS)

Richard Newitter

Truist Financial

$24→$27

Hold

23.23%

Upside

Reiterated

02/23/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (NASDAQ: CYTK) and Tandem Diabetes Care (NASDAQ: TNDM)

David Roman

Goldman Sachs

$25→$28

Hold

27.80%

Upside

Reiterated

02/23/26

Tandem Diabetes price target raised to $28 from $25 at Goldman SachsTandem Diabetes price target raised to $28 from $25 at Goldman Sachs

Frank Takkinen

Lake Street

$14→$50

Buy

128.21%

Upside

Upgraded

02/23/26

Tandem Diabetes upgraded to Buy from Hold at Lake StreetTandem Diabetes upgraded to Buy from Hold at Lake Street

Anthony Petrone

Mizuho Securities

$21→$22

Hold

0.41%

Upside

Reiterated

02/20/26

Analysts Offer Insights on Healthcare Companies: Integer Holdings (NYSE: ITGR), Spyre Therapeutics (NASDAQ: SYRE) and Tandem Diabetes Care (NASDAQ: TNDM)

Jonathan Block

Stifel Nicolaus

$20→$22

Hold

0.41%

Upside

Reiterated

02/20/26

Tandem Diabetes price target raised to $22 from $20 at StifelTandem Diabetes price target raised to $22 from $20 at Stifel

Matt Miksic

Barclays

$56

Buy

155.59%

Upside

Reiterated

02/20/26

Analysts Offer Insights on Healthcare Companies: Talkspace (NASDAQ: TALK), Tandem Diabetes Care (NASDAQ: TNDM) and Ramsay Health Care (Other OTC: RMSYF)

Danielle Antalffy

UBS

$22

Hold

0.41%

Upside

Reiterated

02/20/26

Tandem Diabetes Care: Solid Q4 Beat Offset by PayGo Transition Uncertainty and Competitive Headwinds Supporting Hold Rating

William Plovanic

Canaccord Genuity

$35

Buy

59.74%

Upside

Reiterated

02/20/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Patrick Wood

Morgan Stanley

$23

Hold

4.97%

Upside

Reiterated

02/20/26

Tandem Diabetes Care (TNDM) Receives a Hold from Morgan Stanley

Shagun Singh Chadha

RBC Capital

$30

Buy

36.92%

Upside

Reiterated

02/19/26

RBC Capital Remains a Buy on Tandem Diabetes Care (TNDM)

Mathew Blackman

TD Cowen

$20→$25

Buy

14.10%

Upside

Reiterated

01/26/26

Tandem Diabetes Care: Multi‑Phase Growth Reacceleration Driven by Patch Pump Launch and Margin Recovery Supports Upgraded $25 Target

Lee Hambright

Bernstein

―

Hold

―

Reiterated

01/16/26

Analysts' Top Healthcare Picks: Tandem Diabetes Care (TNDM), CVS Health (CVS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew O'Brien

Piper Sandler

$21→$33

Buy

50.62%

Upside

Upgraded

03/17/26

Tandem Diabetes upgraded to Overweight from Neutral at Piper SandlerTandem Diabetes upgraded to Overweight from Neutral at Piper Sandler

Joanne Wuensch

Citi

$22

Hold

0.41%

Upside

Reiterated

03/11/26

Citi Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM)

Travis Steed

Bank of America Securities

$30→$35

Hold

59.74%

Upside

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (NASDAQ: VIR), Tandem Diabetes Care (NASDAQ: TNDM) and Hims & Hers Health (NYSE: HIMS)

Richard Newitter

Truist Financial

$24→$27

Hold

23.23%

Upside

Reiterated

02/23/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (NASDAQ: CYTK) and Tandem Diabetes Care (NASDAQ: TNDM)

David Roman

Goldman Sachs

$25→$28

Hold

27.80%

Upside

Reiterated

02/23/26

Tandem Diabetes price target raised to $28 from $25 at Goldman SachsTandem Diabetes price target raised to $28 from $25 at Goldman Sachs

Frank Takkinen

Lake Street

$14→$50

Buy

128.21%

Upside

Upgraded

02/23/26

Tandem Diabetes upgraded to Buy from Hold at Lake StreetTandem Diabetes upgraded to Buy from Hold at Lake Street

Anthony Petrone

Mizuho Securities

$21→$22

Hold

0.41%

Upside

Reiterated

02/20/26

Analysts Offer Insights on Healthcare Companies: Integer Holdings (NYSE: ITGR), Spyre Therapeutics (NASDAQ: SYRE) and Tandem Diabetes Care (NASDAQ: TNDM)

Jonathan Block

Stifel Nicolaus

$20→$22

Hold

0.41%

Upside

Reiterated

02/20/26

Tandem Diabetes price target raised to $22 from $20 at StifelTandem Diabetes price target raised to $22 from $20 at Stifel

Matt Miksic

Barclays

$56

Buy

155.59%

Upside

Reiterated

02/20/26

Analysts Offer Insights on Healthcare Companies: Talkspace (NASDAQ: TALK), Tandem Diabetes Care (NASDAQ: TNDM) and Ramsay Health Care (Other OTC: RMSYF)

Danielle Antalffy

UBS

$22

Hold

0.41%

Upside

Reiterated

02/20/26

Tandem Diabetes Care: Solid Q4 Beat Offset by PayGo Transition Uncertainty and Competitive Headwinds Supporting Hold Rating

William Plovanic

Canaccord Genuity

$35

Buy

59.74%

Upside

Reiterated

02/20/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Patrick Wood

Morgan Stanley

$23

Hold

4.97%

Upside

Reiterated

02/20/26

Tandem Diabetes Care (TNDM) Receives a Hold from Morgan Stanley

Shagun Singh Chadha

RBC Capital

$30

Buy

36.92%

Upside

Reiterated

02/19/26

RBC Capital Remains a Buy on Tandem Diabetes Care (TNDM)

Mathew Blackman

TD Cowen

$20→$25

Buy

14.10%

Upside

Reiterated

01/26/26

Tandem Diabetes Care: Multi‑Phase Growth Reacceleration Driven by Patch Pump Launch and Margin Recovery Supports Upgraded $25 Target

Lee Hambright

Bernstein

―

Hold

―

Reiterated

01/16/26

Analysts' Top Healthcare Picks: Tandem Diabetes Care (TNDM), CVS Health (CVS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tandem Diabetes Care

3 Months

xxx

Success Rate

6/10 ratings generated profit

Average Return

+5.22%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +5.22% per trade.

1 Year

Matthew TaylorJefferies

Success Rate

6/10 ratings generated profit

Average Return

+14.43%

reiterated a buy rating 4 months ago

Copying Matthew Taylor's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +14.43% per trade.

2 Years

xxx

Success Rate

10/17 ratings generated profit

Average Return

+91.51%

upgraded a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 58.82% of your transactions generating a profit, with an average return of +91.51% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TNDM Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TNDM has received 7 Buy Ratings, 55 Hold Ratings, and 5 Sell Ratings. TNDM average Analyst price target in the past 3 months is 30.71.

Each month's total comprises the sum of three months' worth of ratings.

TNDM Financial Forecast

TNDM Earnings Forecast

Next quarter’s earnings estimate for TNDM is -$0.44 with a range of -$0.54 to -$0.35. The previous quarter’s EPS was >-$0.01. TNDM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year TNDM has Performed in-line its overall industry.

TNDM Sales Forecast

Next quarter’s sales forecast for TNDM is $242.09M with a range of $236.00M to $260.44M. The previous quarter’s sales results were $290.38M. TNDM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year TNDM has Performed in-line its overall industry.

TNDM Stock Forecast FAQ

What is TNDM’s average 12-month price target, according to analysts?

Based on analyst ratings, Tandem Diabetes Care’s 12-month average price target is 30.71.

What is TNDM’s upside potential, based on the analysts’ average price target?

Tandem Diabetes Care has 40.16% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TNDM a Buy, Sell or Hold?

Tandem Diabetes Care has a consensus rating of Moderate Buy which is based on 6 buy ratings, 9 hold ratings and 0 sell ratings.

What is Tandem Diabetes Care’s price target?

The average price target for Tandem Diabetes Care is 30.71. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $56.00 ,the lowest forecast is $22.00. The average price target represents 40.16% Increase from the current price of $21.91.

What do analysts say about Tandem Diabetes Care?

Tandem Diabetes Care’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of TNDM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Tandem Diabetes Care (TNDM) Stock Forecast & Price Target

TNDM Analyst Ratings

TNDM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Tandem Diabetes Care

TNDM Analyst Recommendation Trends

TNDM Financial Forecast

TNDM Earnings Forecast

TNDM Sales Forecast

TNDM Stock Forecast FAQ

Detailed List of Analyst Forecasts